- Home
- BFST vs IMTX Comparison
BFST vs IMTX Comparison
Compare BFST & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- IMTX
- Stock Information
- Founded
- BFST 2006
- IMTX N/A
- Country
- BFST United States
- IMTX Germany
- Employees
- BFST N/A
- IMTX N/A
- Industry
- BFST Major Banks
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BFST Finance
- IMTX Health Care
- Exchange
- BFST Nasdaq
- IMTX Nasdaq
- Market Cap
- BFST 783.9M
- IMTX 653.9M
- IPO Year
- BFST 2018
- IMTX N/A
- Fundamental
- Price
- BFST $25.16
- IMTX $6.26
- Analyst Decision
- BFST Strong Buy
- IMTX Strong Buy
- Analyst Count
- BFST 3
- IMTX 4
- Target Price
- BFST $30.00
- IMTX $14.67
- AVG Volume (30 Days)
- BFST 88.3K
- IMTX 984.5K
- Earning Date
- BFST 10-23-2025
- IMTX 08-13-2025
- Dividend Yield
- BFST 2.23%
- IMTX N/A
- EPS Growth
- BFST 3.92
- IMTX N/A
- EPS
- BFST 2.51
- IMTX N/A
- Revenue
- BFST $291,096,000.00
- IMTX $152,823,253.00
- Revenue This Year
- BFST $25.00
- IMTX N/A
- Revenue Next Year
- BFST $17.32
- IMTX N/A
- P/E Ratio
- BFST $10.01
- IMTX N/A
- Revenue Growth
- BFST 17.48
- IMTX 83.61
- 52 Week Low
- BFST $20.07
- IMTX $3.30
- 52 Week High
- BFST $30.30
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- BFST 55.16
- IMTX 58.89
- Support Level
- BFST $24.67
- IMTX $5.29
- Resistance Level
- BFST $25.61
- IMTX $5.56
- Average True Range (ATR)
- BFST 0.54
- IMTX 0.35
- MACD
- BFST 0.11
- IMTX 0.04
- Stochastic Oscillator
- BFST 67.89
- IMTX 85.03
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.